EGFR signaling contributes to acquired resistance to CDK4/6 inhibitors in ER plus breast cancer cells in vitro and in vivo

被引：0
|
作者：
Lypova, Nadiia
Lanceta, Lilibeth
Daugherty, Susan
Chesney, Jason
Imbert-Fernandez, Yoannis
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-13-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-13-18
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer
    Guarducci, Cristina
    Cristea, Simona
    Feit, Avery
    Naumenko, Sergey
    Nardone, Agostina
    Ma, Wen
    Russo, Douglas
    Feit, Gabriella Cohen
    Feiglin, Ariel
    Hermida-Prado, Francisco
    Sherman, Shira
    Brown, Myles
    Michor, Franziska
    Jeselsohn, Rinath
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER plus breast cancer
    Sudhan, Dhivya R.
    Chatterjee, Sumanta
    Kim, Jiwoong
    Wang, Yunguan
    Kandagatla, Vishal
    Ye, Dan
    Lin, Chang-Ching
    Zanudo, Jorge Gomez Tejeda
    Jain, Esha
    Marin, Arnaldo
    Servetto, Alberto
    Lee, Kyung-min
    Povedano, Juan Manuel
    McFadden, David
    Barrett, Alex
    Wagle, Nikhil
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2022, 82 (04)
  • [23] Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER plus breast cancer
    De Angelis, Carmine
    Cataldo, Maria Letizia
    Nardone, Agostina
    Veeraraghavan, Jamunarani
    Fu, Xiaoyong
    Nanda, Sarmistha
    Qin, Lanfang
    Sethunath, Vidyalakshmi
    Pereira, Resel
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Rimawi, Mothaffar F.
    Jeselsohn, Rinath
    Osborne, Kent
    Schiff, Rachel
    CANCER RESEARCH, 2020, 80 (04)
  • [24] CDK4/6 inhibitors in breast cancer
    Dukelow, Tim
    Kishan, Divya
    Khasraw, Mustafa
    Murphy, Conleth G.
    ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
  • [25] High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER plus breast cancer
    De Angelis, Carmine
    Fu, Xiaoyong
    Cataldo, Maria Letizia
    Nardone, Agostina
    Jansen, Valerie M.
    Veeraraghavan, Jamunarani
    Nanda, Sarmistha
    Qin, Lanfang
    Sethunath, Vidyalakshmi
    Pereira, Resel
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Donaldson, Joshua
    Selenica, Pier
    Brown, David N.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Park, Ben H.
    Hurvitz, Sara A.
    Slamon, Dennis J.
    Rimawi, Mothaffar F.
    Jeselsohn, Rinath
    Osborne, Kent
    Schiff, Rachel
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.
    Razavi, Pedram
    dos Anjos, Carlos Henrique
    Brown, David N.
    Qing, Li
    Ping, Christina
    Herbert, Joshua
    Colon, Jodecy
    Liu, Dazhi
    Mao, Maiya
    Norton, Larry
    Scaltriti, Maurizio
    Solit, David B.
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Jhaveri, Komal L.
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [28] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [29] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [30] Glucose Metabolic Reprogramming of ER+ Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Mannelli, Michele
    Parri, Matteo
    Comito, Giuseppina
    Ippolito, Luigi
    Giannoni, Elisa
    Bonechi, Martina
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Chiarugi, Paola
    Morandi, Andrea
    CELLS, 2020, 9 (03)
12345